Home

Health Care

Biotechnology: Toward a Sustainable Future

Sustainable development is no small undertaking for international companies looking to meet today’s energy, food and environmental needs without compromising the Earth’s resources or its future. The innovative solution these corporate leaders are turning to is biotechnology, whether it’s to augment agricultural productivity, reduce greenhouse gas emissions, create an innovative disease therapy or diminish the use of pesticides.

Health Care Reform: Biotech Industry Supports Universal Access to Health Care

With the Senate no longer filibuster-proof, the future of the health care bill is fairly murky. In early January, Congress was deep into negotiations on a final version, which includes language that would be a major shot in the arm for the biotechnology industry and provide great benefits to patients.

The Next Big Thing: Targeted Treatments

Personalized medicine involves using the advanced tools of molecular genetics and diagnostics to predict how patients will respond to drugs, reducing harmful side effects and increasing benefit. In addition, the panoply of technologies enabling this revolution in medicine can produce a personal medical profile that can guide the physician toward selecting the most appropriate drug or treatment regimen and help individuals stave off diseases before they manifest themselves. This dual combination of diagnostic and treatment technologies is at the heart of personalized medicine and is poised to transform healthcare dramatically.

10 to Watch: Hot Biotech Prospects

Technological innovation promises to redefine health care as we know it.

BioBytes: Biotechnology and Vaccines

New vaccines employing biotech innovations are changing the way we prevent illness.

Biotech is Still Golden in the Golden State

We all know that California has been hit hard by the current recession. Sadly most of the state is facing dire economic realities that go much deeper than that.  However, its status as the world’s undisputed epicenter of biotechnology has not been tarnished one bit, according to a new survey released by the California Healthcare Institute.

Podcast with Dr. David Agus
Podcast with Dr. Kim Hunter-Schaedle, Children’s Tumor Foundation
Podcast with Steve Perrin from ALS Therapy Development Institute
Podcast with Dr. Louise Perkins, Multiple Myeloma Research Foundation
RNAi: Creating a New Approach to Medicine

Ttoday, modern biotechnology offers the opportunity to go well beyond blocking the production of proteins to actually silencing them.

Podcast on BIO's Public Policy Priorities for 2010

Danny Levine of the Burrill Report conducted a podcast with BIO President & CEO Jim Greenwood today on BIO's public priorities for 2010.

BioBytes: What are biosimilars?

Biosimilars, also known as follow-on biologics, may eventually expand access and provide patients a more affordable alternative to innovative, lifesaving medicines. 

PBS To Highlight Rare Disease Diagnosis Through Biotech
Data Exclusivity and Biotech Competition: Separating Fact from Fiction

Myths abound regarding data exclusivity and the ability of an innovator to extend the period of data exclusivity as provided in the health care reform bill passed by the U.S. House of Representatives and legislation currently under consideration in the Senate.

Letters, Testimony & Comments

PBRER: BIO Comments on Postmarket Periodic Safety Reports in the International Conference on Harmonisation E2C(R2) Format
May 8 2013
  Dear Sir/Madam:   The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for...
Benefit-Risk: BIO Comments on FDA's Prescription Drug User Fee Act V Benefit-Risk Plan
May 7 2013
Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to...
Recombinant DNA: BIO Comments on WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology
April 19 2013
  The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the “WHO Guidelines on the Quality...
Immunogenicity: BIO Comments on Draft Guidance on Immunogenicity Assessment for Therapeutic Protein Products
April 12 2013
Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to...
Sunshine: BIO Files Comments on Estimated Burden of complying with Section 6002 of the Affordable Care Act (“the Sunshine Act”)
April 8 2013
BIO supports the goals of the Affordable Care Act (ACA) in providing greater transparency regarding financial relationships with...
More Letters, Testimony & Comments →

Press Releases

BIO Praises U.S. Senate for Passing the Pandemic and All-Hazards Preparedness Reauthorization Act
February 28 2013
WASHINGTON, DC – February 28, 2013 –The Biotechnology Industry Organization (BIO) lauds the Senate for...
BIO Praises The House of Representatives for Approving H.R. 307, the Pandemic and All-Hazards Preparedness Reauthorization Act
January 25 2013
The Biotechnology Industry Organization lauds the House of Representatives for passing H.R. 307, the Pandemic and All...
PDUFA V Sets New Course for Regulatory Science – Joint BIO/PhRMA Statement
October 1 2012
Washington, D.C. (October 1, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and...
IFPMA, BIO and WADA Advance Anti-Doping Collaboration with the Launch of 2 Fields 1 Goal Campaign
July 23 2012
Groups Issue Booklet to Help Biotechnology and Pharmaceutical Companies Identify Pipeline Medicines with Doping...
Supreme Court Affordable Care Act Ruling Must Now Lead to Implementation That Will Promote Innovation and Expand Access
June 28 2012
  Pleased to move forward on biosimilars pathway Washington, D.C. (June 28, 2012) –Biotechnology...
More Press Releases →